11th May 2017

ReNeuron secure £1.8m Innovate UK grant

Cell therapy company ReNeuron, which relocated to new headquarters in Bridgend last year, has secured a £1.8m grant from Innovate UK.

The ‘Cell2Sell’ grant has been awarded under Innovate UK’s Cell & Gene Therapies Industrial Manufacture grant scheme. It will fund a programme of work to be led by ReNeuron, working with the Cell & Gene Therapy Catapult.

The investment will support development activities relating to up-scaled commercial manufacture of ReNeuron’s cell therapy candidates.

These include the development of robust manufacturing processes utilising next generation technology and techniques that will enable the production of ReNeuron’s therapeutic candidates at a commercial scale.

Sharon Grimster, general manager, Wales, at ReNeuron, said: “We are delighted to have won this prestigious and highly competitive grant from Innovate UK. It enables us to further pursue and optimise our cell therapy manufacturing processes as our therapeutic programmes get closer to market.

“The grant award will also assist ReNeuron in the execution of its strategy to ultimately bring the manufacture of its cell therapy candidates in-house to meet demand following market approval.”

ReNeuron relocated to new headquarters, research labs and manufacturing facilities on the Pencoed Business Park in Bridgend during 2016, supported by the Welsh Government.

View ReNeuron’s profile here.